Skyhawk's Huntington's Drug Shows Stabilization in Key Clinical Metrics
Event summary
- Skyhawk's SKY-0515 demonstrated stabilization or improvement across all cUHDRS subcomponents in a 12-month Phase 1/2 trial for Huntington's disease.
- 65% of patients and 50% of clinicians reported disease improvement, with no observed worsening at 12 months.
- SKY-0515 achieved up to 69% reduction in mutant huntingtin protein and 26% reduction in PMS1 mRNA.
- FALCON-HD pivotal trials (Phase 2/3) are underway, with enrollment complete in Australia/New Zealand and ongoing globally.
The big picture
Skyhawk's data suggests SKY-0515 could be the first oral therapy to slow Huntington's progression, addressing a critical unmet need in neurodegenerative disease. The results position Skyhawk as a key player in RNA-modulating therapies, though competition from gene-editing technologies remains intense. Success would validate its SKYSTAR platform for other intractable neurological disorders.
What we're watching
- Regulatory Pathway
- Whether the FALCON-HD pivotal trial results will support accelerated approval given the lack of current disease-modifying treatments.
- Competitive Positioning
- How Skyhawk's oral therapy differentiates against emerging gene-silencing approaches in Huntington's disease.
- Platform Expansion
- The pace at which Skyhawk advances additional SKYSTAR-derived programs into clinical development by late 2027.
Related topics